Phase 1 Multiple Sclerosis Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You are between 18 and 60 years old at the time of signing the consent form
- You are able and willing to give written consent to take part in the study
- Your overall physical health and body functions are at an acceptable level at the time of initial assessment
- (For the relapsing MS group) You have been diagnosed with relapsing MS or a relapsing, active form of secondary progressive MS, based on specific medical criteria
- (For the relapsing MS group) Your level of disability, measured on a standard scale, is at or below a certain moderate threshold at the time of initial assessment
- (For the relapsing MS group) You have shown signs of active disease (such as relapses or changes on MRI scans) within the past 2 years, or you have been unable to tolerate a high-strength MS treatment taken for at least 6 months
- (For the progressive MS group) You have been diagnosed with primary progressive MS or a non-relapsing form of secondary progressive MS, based on specific medical criteria
- (For the progressive MS group) Your level of disability falls within a certain moderate-to-significant range on a standard scale at the time of initial assessment
- (For the progressive MS group) You have not responded well enough to at least one high-strength MS treatment taken for at least 6 months, or you were unable to tolerate it
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have previously received a type of cell therapy called CAR-T or CAR-NK treatment
- You had your spleen removed within the 12 months before signing the consent form
- You have received a solid organ transplant (such as a kidney or liver) at any point, or you are currently on a waiting list for one
- You have previously had a stem cell transplant using your own cells, or have had a treatment called total lymphoid irradiation
- You have a significant heart condition that the study doctor feels would put you at unnecessary risk (confirm with trial site)
- You have another condition affecting the brain or nervous system — such as epilepsy, seizures, stroke, dementia, Parkinson's disease, psychosis, or other neurological diseases — including a history of seizures even if currently well managed with medication
- You have a significant mental health condition, either currently or in the past
- You have another immune system disease that required ongoing treatment to suppress the immune system
- You have had significant or active bleeding problems within the 90 days before your initial assessment
- You have a history of cancer or are currently being treated for a previous cancer
- You have an inherited condition that affects how your immune system works
- You have tested positive for HIV or HTLV, or have any history of either infection
- You currently have an active hepatitis infection (such as hepatitis B or C)
- You have had major surgery within 4 weeks before certain study procedures, or have surgery planned during the study or within 4 weeks after receiving the study treatment
- You are pregnant, breastfeeding, or planning to become pregnant during the study or within 1 year after receiving the study treatment
- The study doctor considers it unsafe or not possible for you to have a spinal fluid sample (lumbar puncture) taken
- You have a medical reason that prevents you from having a lumbar puncture
- You are unwilling, unable, or it is unsafe for you to have MRI scans as required by the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-240-9479
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS); Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS); Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS); Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.